Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ferring International Center S A is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, which centralizes the company's current prosecution efforts. Such a focused portfolio allows for a targeted approach to addressing examiner concerns within this specific technology sector.
WANG, RUIXUE is the busiest examiner for the company, currently overseeing 1 pending office action. As the only examiner with an active matter, WANG, RUIXUE represents the primary point of contact for the company's current interactions with the patent office. The outcome of this 1 pending action will be a significant indicator of the company's success in the Biotechnology & Pharmaceuticals area.
The portfolio's active prosecution is situated within 1 distinct art unit. This concentration in 1 distinct art unit means that the company is dealing with a specific set of examination standards and technical expertise. By focusing on the 1 pending office action in this unit, the company can tailor its arguments to the specific preferences and precedents established by the assigned examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, RUIXUE | 1 | 55.9% | +19.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18769686 | METHODS OF PRODUCING RECOMBINANT ADENOVIRUS VECTORS | WANG, RUIXUE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18769686 | METHODS OF PRODUCING RECOMBINANT ADENOVIRUS VECTORS | WANG, RUIXUE | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18769686 | METHODS OF PRODUCING RECOMBINANT ADENOVIRUS VECTORS | WANG, RUIXUE | 1672 | §102§103§112 | Non-Final OA | — | Pending | Jul 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFerring International Center S A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ruixue Wang has the most, with 1 of Ferring International Center S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
